CC-220
Drug
Celgene Corporation
Total Payments
$5.4M
Transactions
266
Doctors
24
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.5M | 107 | 15 |
| 2018 | $1.1M | 93 | 13 |
| 2017 | $1.8M | 66 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.4M | 246 | 99.7% |
| Consulting Fee | $15,898 | 11 | 0.3% |
| Food and Beverage | $466.48 | 9 | 0.0% |
Payments by Type
Research
$5.4M
246 transactions
General
$16,364
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (CC-220-SLE-002) | Celgene Corporation | $1.0M | 3 |
| CC-220-SLE-002 - A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | Celgene Corporation | $698,450 | 3 |
| A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma (CC-220-MM-001) | Celgene Corporation | $667,015 | 7 |
| Phase 1 | Celgene Corporation | $538,901 | 0 |
| CC-220-SLE-001 | Celgene Corporation | $420,939 | 3 |
| A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects (CC-220-CP-007) | Celgene Corporation | $388,927 | 0 |
| CC-220-MM-001 | Celgene Corporation | $309,468 | 0 |
| CC-220-CP-006 | Celgene Corporation | $286,578 | 0 |
| A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics ofCC-220in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects (CC-220-CP-007) | Celgene Corporation | $189,612 | 0 |
| CC-220-SLE-001 - A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Sys | Celgene Corporation | $159,403 | 1 |
| CC-220-SLE-002 | Celgene Corporation | $155,619 | 0 |
| CC-220-MM-001 - A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Com | Celgene Corporation | $126,996 | 3 |
| CC-220-CP-006 - A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C]-CC-220 in Healthy Male Subjects | Celgene Corporation | $124,776 | 0 |
| A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus (CC-220-SLE-001) | Celgene Corporation | $106,491 | 1 |
| CC-220-SLE-001; CC-220-SLE-002 | Celgene Corporation | $90,000 | 0 |
Top Doctors Receiving Payments for CC-220
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $5.1M | 224 |
| , M.D | Rheumatology | San Leandro, CA | $176,962 | 5 |
| , MD | Specialist | Plantation, FL | $86,514 | 3 |
| , MD | Specialist | Brandon, FL | $27,288 | 2 |
| , DO | Internal Medicine | Lansing, MI | $15,005 | 1 |
| , MD | Rheumatology | Oklahoma City, OK | $6,508 | 3 |
| , MD | Hematology & Oncology | Scottsdale, AZ | $4,141 | 2 |
| , M.D | Hematology | Atlanta, GA | $4,141 | 2 |
| , MD | Internal Medicine | Detroit, MI | $4,141 | 2 |
| , M.D | Rheumatology | Beverly Hills, CA | $4,022 | 5 |
| , M.D | Rheumatology | New Hyde Park, NY | $3,500 | 2 |
| , MD | Rheumatology | Manhasset, NY | $2,440 | 1 |
| , MD | Rheumatology | Summit, NJ | $1,432 | 2 |
| , MD | Hematology & Oncology | Ann Arbor, MI | $1,144 | 1 |
| , M.D | Medical Oncology | Baltimore, MD | $1,144 | 1 |
| , MD | Hematology | Hackensack, NJ | $1,144 | 1 |
| , M.D | Medical Oncology | New York, NY | $1,144 | 1 |
| , M.D | Specialist | New York, NY | $466.00 | 1 |
| , M.D | Internal Medicine | Pembroke Pines, FL | $85.21 | 1 |
| , MD | Rheumatology | Gainesville, FL | $74.80 | 1 |
| , M.D | Rheumatology | Fort Myers, FL | $66.06 | 1 |
| , MD | Rheumatology | Albuquerque, NM | $60.48 | 1 |
| , MD | Rheumatology | Albuquerque, NM | $60.48 | 1 |
| , M.D | Rheumatology | Skokie, IL | $40.04 | 1 |
| , M.D | Rheumatology | Charlottesville, VA | $23.33 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $5.4M
Product Information
- Type Drug
- Total Payments $5.4M
- Total Doctors 24
- Transactions 266
About CC-220
CC-220 is a drug associated with $5.4M in payments to 24 healthcare providers, recorded across 266 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $2.5M was paid across 107 transactions to 15 doctors.
The most common payment nature for CC-220 is "Unspecified" ($5.4M, 99.7% of total).
CC-220 is associated with 15 research studies, including "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (CC-220-SLE-002)" ($1.0M).